人乳头瘤病毒疫苗在成年女性中的长期有效性:真实世界场景研究
本研究在泰国曼谷20-45岁女性中开展回顾性队列研究,将493名接种过二价或四价HPV疫苗者与500名未接种者按基线年份匹配,随访约7年。结果显示疫苗对HPV 16/18相关ASC-US+的 effectiveness 为88.0%(95%CI 2.0-98.5),对HPV 16/18阳性的 effectiveness 为84.6%(95%CI 43.5-95.8)。
要点
- 接种组未出现HPV 16/18相关LSIL+,未接种组出现4例。
- 疫苗对HPV 16/18相关ASC-US+的 effectiveness 为88.0%(95%CI 2.0-98.5)。
- 疫苗对HPV 16/18阳性的 effectiveness 为84.6%(95%CI 43.5-95.8)。
核心结论
- 在发展中国家真实世界场景中,HPV疫苗在成年女性中显示出高有效性。
- 当疫苗供应不受限时,应进一步探索该年龄组成年女性的免费HPV疫苗接种。
研究设计与样本
- 回顾性队列研究,纳入泰国曼谷20-45岁女性,接种组与未接种组按基线年份匹配。
- 共纳入993名参与者,接种组493名,未接种组500名,招募时间为2018年至2019年。
- HPV/Pap检测结果来自医疗记录和/或研究现场宫颈样本采集。
- 使用多变量Cox回归分析计算调整后风险比。
主要发现
- 接种组基线中位年龄33岁(IQR 27-38),未接种组34岁(IQR 30-38)。
- 接种组中位随访7.3年(IQR 6.1-8.6),未接种组7.2年(IQR 5.8-8.9)。
- 接种组单身女性占29.2%,未接种组占13.2%(P < 0.001);接种组大学毕业生占83.2%,未接种组占75.4%(P = 0.009)。
- 两组个人月收入>20,000泰铢者比例相似(63.9% vs. 62.4%,P = 0.685)。
- 接种组无HPV 16/18相关LSIL+病例,未接种组有4例。
临床怎么用
- 作者认为,在疫苗供应不受限时,应进一步探索该年龄组成年女性的免费HPV疫苗接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to determine the real-world effectiveness of bi- or quadrivalent human papillomavirus (HPV) vaccines in Thai adult women ≥5 years post-vaccination in reducing HPV 16/18-associated low-grade squamous intraepithelial lesions or worse (LSIL+), atypical squamous cells of undetermined significance or worse (ASC-US+), and HPV 16/18 positivity. METHODS: A retrospective cohort study was conducted among Thai women aged 20-45 years in Bangkok. The vaccinated and unvaccinated groups were matched according to baseline years. HPV/Pap test results were collected from the medical records and/or obtained by cervical sample collection at the study sites. Adjusted hazard ratios were measured using multivariable Cox regression analyses. RESULTS: A total of 993 participants (493 vaccinated and 500 unvaccinated) were enrolled from 2018 to 2019. The median ages at baseline of the vaccinated and unvaccinated groups were 33 years (interquartile range [IQR] 27-38) and 34 years (IQR 30-38), respectively. The median follow-up periods were 7.3 years (IQR 6.1-8.6) and 7.2 years (IQR 5.8-8.9) for the vaccinated group and the unvaccinated group, respectively. More women in the vaccinated group were single (29.2% vs. 13.2%, P < 0.001) and university graduates (83.2% vs. 75.4%, P = 0.009). The vaccinated and unvaccinated groups had similar personal monthly incomes (>20,000 THB/month, 63.9% vs. 62.4%, respectively, P = 0.685). There were no cases of HPV 16/18-associated LSIL+ in the vaccinated group, whereas there were four cases in the unvaccinated group. HPV vaccine effectiveness was 88.0% (95% CI 2.0-98.5) in the reduction of HPV 16/18-associated ASC-US+, and 84.6% (95% CI 43.5-95.8) in the reduction of HPV 16/18 positivity. CONCLUSIONS: HPV vaccine effectiveness was high in adult women in a real-world scenario in a developing country. Free HPV vaccination in adult women in this age group should be further explored when vaccine supplies are not limited. (HPV: human papillomavirus. LSIL+: low-grade squamous intraepithelial lesion or worse. ASC-US+: atypical squamous cells of undetermined significance or worse).
引用
- Lee GY, Inthasorn P, Laowahutanont P, et al. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario. Vaccine. 2022. PMID: 35190207. doi:10.1016/j.vaccine.2022.02.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。